Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04646460
Other study ID # 230137
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 1, 2024
Est. completion date December 1, 2024

Study information

Verified date November 2023
Source Trustees of Dartmouth College
Contact Tor D Wager, PhD
Phone 603-646-2196
Email Tor.D.Wager@Dartmouth.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this experiment, the investigators study the brain pathways underlying several promising context interventions that enhance the strength of placebo effects. Specifically, the investigators examine the separate and joint effects of two of the most powerful context interventions: Social modeling-observing someone else being effectively treated-and prior treatment success or failure experiences. Participants will be randomized into 4 groups (Social modeling: observed success vs. observed failure and Conditioning: experienced success vs. experienced failure). The objectives are to investigate the placebo effect on pain relief and aversive image stimuli between and within-subjects. Each group will undergo a behavioral induction phase, fMRI placebo test phase, and an identical 3-month follow up fMRI placebo test phase. Follow-up assessment will provide some of the first evidence on predictors of the durability of placebo and context interventions.


Description:

Background: Humans are highly social creatures, and others' behavior and experiences can have profound effects on symptoms, physiology, and behavior. Social modeling-watching a similar other experience treatment benefits-may also strongly enhance placebo effects and their durability over time, particularly when combined with other context interventions. Social influences can affect core motivational circuitry (e.g., nAC and amygdala), shape learning trajectories, and appears to have distinct mechanisms from other (e.g., conditioning) manipulations. Their impact on brain mechanisms of placebo has not been studied. Likewise, initial perceived treatment success or failure can powerfully shape learning trajectories and placebo analgesia. Initial failure experiences with a treatment type (e.g., pill) may explain some of the treatment failures in studies that (a) attempt to wash out placebo responses with ineffective pills before starting verum drug, or (b) re-randomize non-responders to different pills, as in the STAR*D antidepressant study. But the effects of initial success/failure experiences on the brain mechanisms of placebo effects have not been studied. Design: In an initial observation phase, participants will watch a video of another participant ("demonstrator") undergoing the baseline assessment and placebo test procedure. Next, participants will undergo a conditioning phase. The intervention is a 2 x 2 factorial between-groups manipulation (N = 30 per group) of social modeling (Observed treatment success vs. failure) and participants' initial success experience (Experienced success vs. failure). Thus, the demonstrator will either show strong signs of pain relief during placebo (Observed-Success condition) or no signs of relief (Observed-Failed treatment). During the conditioning phase, all participants will experience high-intensity heat before placebo treatment and then either low-intensity heat after application of a placebo cream, as in the investigator's and others' past work, creating experience of pain relief (Experienced-Success condition) or they will not experience relief (i.e., temperatures will not be lowered; Experienced-Failed treatment). In a subsequent fMRI test phase, participants experience painful heat and aversive IAPS images (as a transfer/specificity test) during fMRI, on skin sites treated with Control and Placebo creams, in a Control -> Placebo -> Control block design as in past research. Finally, a 3-month follow-up fMRI test phase, without additional observation or conditioning, will assess durability of brain and behavioral placebo effects.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date December 1, 2024
Est. primary completion date December 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - No current psychiatric or major neurological diagnosis - No reported substance abuse within the last six months - Capable of performing experimental tasks (e.g., are able to read, able to cooperate with fMRI examination) - Fluent or native speakers of English - No current or recent history of pathological pain or reported neurological disorders - Abstained from alcohol and substance use for 48 hours - Provided informed consent - Passed fMRI screening test Exclusion Criteria: - Current presence of pain - Current or past history of primary psychiatric disorder - Current or past history of psychoactive substance abuse or dependence - Dementias - Movement disorders except familial tremor - CNS infection - CNS vasculitis, inflammatory disease or autoimmune disease - CNS demyelinating disease (e.g. multiple sclerosis) - Space occupying lesions (mass lesions, tumors) - Congenital CNS abnormality (e.g. cerebral palsy) - Seizure disorder - History of closed head trauma with loss of consciousness - History of cerebrovascular disease (stroke, TIAs) - Abnormal MRI (except changes accounted for by technical factors or UBOs) - Neuroendocrine disorders (e.g., Cushings disease) - Uncorrected hypothyroidism or hyperthyroidism - Current or past history of cancer - Recent history (within two years) of myocardial infarction, severe cardiovascular disease, or currently active cardiovascular disease (e.g. angina, cardiomyopathy) - Uncontrolled hypertension or hypotension - Chronic pain syndromes - Chronic fatigue syndromes - Subjects unable to tolerate the scanning procedures (e.g., claustrophobia) - Prior treatment within the last month with any of the following: antidepressants, mood stabilizers, glucocorticoids, opiates - Prior treatment with any of the following: antipsychotics, isoniazid, centrally active antihypertensive drugs (e.g. clonidine, reserpine) - Metal in body or prior history working with metal fragments (e.g., as a machinist) - Pregnancy - Any other contraindications for MRI examination (e.g., metallic implants such as pacemakers, surgical aneurysm clips, or known metal fragments embedded in the body) - Claustrophobia

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Observed Success
The demonstrator in video gets a placebo treatment, "Levoderm" analgesic cream, which will be shown to be effective at relieving pain.
Observed Failure
The demonstrator in the video gets the same placebo treatment, but shows little to no effectiveness from the placebo for relieving pain.
Experienced Success
The participant will receive reduced stimulus intensities after the placebo cream treatment to reinforce the effectiveness of the cream.
Experienced Failure
The participant will not receive reduced stimulus intensities after the placebo treatment, so the cream is not reinforced as effective.

Locations

Country Name City State
United States Dartmouth College Hanover New Hampshire

Sponsors (1)

Lead Sponsor Collaborator
Trustees of Dartmouth College

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intervention effects on pain ratings Pain ratings will be given on a 0-100 scale. 0 being "no pain at all" and 100 being "most pain imaginable in the context of this study." Immediately after pain stimuli
Primary Intervention effects on aversive image ratings Aversive ratings will be given on a 0-100 scale. 0 being "not unpleasant at all" and 100 being "very unpleasant." Immediately after aversive image stimuli
Primary Brain: signature responses to pain and aversive images A priori regions of interest response from the brain (fMRI) patterns to the pain and aversive images. Immediately after pain/image stimuli
Secondary Skin conductance Skin conductance response (SCR) will be recorded during the task. Immediately after pain stimuli
Secondary Heart rate Heart rate will be recorded during the task. Immediately after pain stimuli
Secondary Whole-brain maps of intervention effects Exploratory brain analysis will include univariate voxel-wise maps comparing participant groups with a threshold of q < 0.05, False Discovery Rate (FDR)-corrected. Immediately after pain stimuli
Secondary CliexaEase App ratings Participants click an "I feel" button to display a list of feelings (i.e., happiness, sadness, pain, fear, stress, etc.), and then can drag a feeling bubble to a bodily location (or to a location indicating "not felt in the body"), and then rate the intensity of the feeling on a visual analog scale. This assessment is open-ended to minimize demand characteristics. Daily for: 2 weeks before scan, 2 weeks after last scan. Weekly for 1 year after last session.
Secondary Interpersonal Reactivity Index A rating of dispositional empathy with responses answered on a 5-point Likert scale ranging from "does not describe me well" to "describes me very well." Higher scores indicate more empathetic responses. Within two weeks before first fMRI scan
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Terminated NCT04356352 - Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain Phase 2/Phase 3
Completed NCT04748367 - Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care N/A
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04466111 - Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05868122 - A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy Phase 3
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Completed NCT03273114 - Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain N/A
Enrolling by invitation NCT06087432 - Is PNF Application Effective on Temporomandibular Dysfunction N/A
Completed NCT05508594 - Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 Phase 2/Phase 3
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Active, not recruiting NCT03472300 - Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
Completed NCT03678168 - A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries N/A
Completed NCT03286543 - Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System N/A
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Completed NCT02913027 - Can We Improve the Comfort of Pelvic Exams? N/A
Terminated NCT02181387 - Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor? Phase 4
Recruiting NCT06032559 - Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment Phase 3
Active, not recruiting NCT03613155 - Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care